• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure

byZain Cheema
May 2, 2023
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized clinical trial, among 2859 patients, death occurred in 26.1% of patients randomized to torsemide and 26.2% of patients randomized to furosemide over a median follow-up period of 17.4 months, with no significant difference between groups.

2. Rates of hospitalizations in the torsemide and furosemide groups were 37.5% and 40.4%, respectively.

Evidence Rating Level:1 (Excellent)

Study Rundown: Heart failure (HF) is commonly characterized by symptoms of congestion and volume overload that can present as dyspnea and edema. Current guidelines recommend the use of diuretics for the treatment of congestion in symptomatic patients with HF. Furosemide is the most commonly prescribed diuretic for HF, however, recent clinical data suggest potential benefits of torsemide when compared when furosemide. The objective of the TRANSFORM-HF (Torsemide Comparison with Furosemide for Management of Heart Failure) trial was to compare the effectiveness of torsemide with furosemide in patients hospitalized with HF. A total of 2859 participants hospitalized with HF were recruited between 2018 and 2022, with follow-up through 30 months for death and 12 months for hospitalizations. Patients were randomized to receive either torsemide (n=1431) or furosemide (n=1428). The main outcome was all-cause mortality, and secondary outcomes included all-cause hospitalization and total hospitalizations assessed over 12 months. Death occurred in 26.1% of patients in the torsemide group, and 26.2% of patients in the furosemide group. 12 months post-randomization, all-cause mortality or all-cause hospitalization occurred in 47.3% of patients in the torsemide group and 49.3% of patients in the furosemide group. When compared with furosemide, torsemide did not result in a significant difference in all-cause mortality over 12 months.  A major strength of this trial was that over 30% women were recruited for both intervention groups. Interpretation of these findings may be limited, however, due to the loss to follow-up, participant crossover and non-adherence.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

RELATED REPORTS

Mineralocorticoid receptor antagonists reduce hospitalizations in patients with heart failure with preserved or mildly reduced ejection fraction

Bayer’s Kerendia demonstrates success in phase 3 clinical trials for treatment of heart failure

Semaglutide reduces heart failure events in patients with preserved ejection fraction

In-Depth [randomized controlled trial]: This study investigated whether torsemide resulted in decreased mortality compared with furosemide in patients hospitalized for HF. The TRANSFORM-HF trial recruited a total of 2859 patients that were randomized to receive either torsemide (n = 1431) or furosemide (n = 1428). The primary outcome was all-cause mortality, with secondary outcomes including all-cause hospitalization and total hospitalizations assessed over 12 months. Death occurred in 373 of 1431 patients (26.1%) in the torsemide group and 374 of 1428 patients (26.2%) in the furosemide group (HR, 1.02 [95% CI, 0.89-1.18]; P = .76). All-cause mortality or all-cause hospitalization occurred in 677 patients (47.3%) in the torsemide group and 704 patients (49.3%) in the furosemide group (HR, 0.92 [95% CI, 0.83-1.02]). There were 940 total hospitalizations among 536 participants (37.5%) in the torsemide group and 987 total hospitalizations among 577 participants (40.4%) in the furosemide group (rate ratio, 0.94 [95% CI, 0.84 – 1.07]). The post hoc analysis addressed competing risks for all-cause hospitalizations over a 12-month period and determined a hazard ratio of 0.88 (95% CI, 0.78 – 0.99) with torsemide compared with furosemide.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: congestive heart failurediureticsfurosemidetorsemideTRANSFORM-HF
Previous Post

Community-based adult vision screening program increases access to eye care

Next Post

Higher body mass index may be associated with altered vitamin D levels and metabolism

RelatedReports

Quick Take: Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm
Cardiology

Mineralocorticoid receptor antagonists reduce hospitalizations in patients with heart failure with preserved or mildly reduced ejection fraction

October 18, 2024
Pharma

Bayer’s Kerendia demonstrates success in phase 3 clinical trials for treatment of heart failure

October 3, 2024
Parental conceptions of weight are becoming increasingly inaccurate
Cardiology

Semaglutide reduces heart failure events in patients with preserved ejection fraction

September 24, 2024
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Cardiology

Semaglutide reduces cardiovascular events in patients with atherosclerotic disease and obesity

September 5, 2024
Next Post
Sleep duration inversely related to childhood type 2 diabetes risk makers

Higher body mass index may be associated with altered vitamin D levels and metabolism

Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients

Disposable elevator cap duodenoscopes may reduce contamination in endoscopic retrograde cholangiopancreatography – the ICECAP trial

Evidence-based interventions for pediatric asthma successfully adapted for community health centers

2 Minute Medicine Rewind January 23, 2023

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
  • Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.